<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00358072</url>
  </required_header>
  <id_info>
    <org_study_id>NILG-ALL 09/00</org_study_id>
    <nct_id>NCT00358072</nct_id>
  </id_info>
  <brief_title>Treatment of Adult ALL With an MRD-directed Programme.</brief_title>
  <official_title>Treatment of Adult Acute Lymphoblastic Leukemia Using a Post-remission Programme Whose Intensity Varies Depending on the Risk Class Defined on the Basis of Minimal Residual Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Italy Leukemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Associazione Italiana per la Ricerca sul Cancro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern Italy Leukemia Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to optimize the concept of risk-oriented postremission consolidation therapy,
      by offering (i) standard consolidation-maintenance to patients at lowest risk of relapse as
      defined by MRD(Minimal Residual Disease) negative status, and (ii) allogeneic stem cell
      transplantation (related/unrelated donor available) or multicycle high-dose therapy with
      autologous blood stem cell transplant (no donor) to patients at highest risk of relapse as
      defined by MRD+ status.

      The prognostic role of MRD evaluation in unselected patients will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Improved outcome of adult ALL through the application of:

        -  Risk-adapted induction (cycle no. 1: IVAP i.e
           idarubicin-vincristine-asparaginase-prednisone, plus fractionated cyclophosphamide in
           T-ALL,and imatinib in Ph/BCR-ABL+ ALL)

        -  Risk stratification (clinical) according to morphology, immunophenotype, cytogentics and
           molecular biology results. Standard risk (SR) is defined by pre-B CD10+ phenotype,
           Ph/BCR-ABL- status, and a blast count &lt;10x10e9/L. All other subgroups are HR (high-risk)
           except for Ph/BCR-ABL+ and t(4;11)+ ALL (VHR, very high-risk)

        -  Homogeneous early consolidation programme including both conventional therapy with
           idarubicin-vincristine-cyclophosphamide-dexamethasone/prednisone(cycles no. 2,3,5,6,8)
           and high-dose treatemt with MTX/Ara-C (cycles no. 4,7) and meningeal prophylaxis (triple
           intrathecal therapy x8-12, skull irradiation), plus imatinib in Ph+ ALL (Phase A).
           Autologous bllo stem cells are mobilized and cryopreserved after cycle no. 4.

        -  Serial evaluation of minimal residual disease (MRD) with RQ-PCT technology, aiming to
           define in individual patients the rate of reduction during early consolidation. The
           molecular study was centralized and aimed at obtaining one or more patient-specific
           probe(s)with a sensitivity of at least 10e-3. Patient bone marrow was sampled for MRD
           analysis at timepoints 13 i.e. after cycles no.3,5, and 7. Only patients with a negative
           result at timepoint 3 and a negative/low positive (&lt;10e-4) result at timepoint 3 are
           considered MRD-, all other combinations being regarded MRD+.

        -  Phase B therapy according to MRD results and ALL subset:

             -  MRD- nonPh/t(4;11): standard maintenance

             -  MRD+ nonPh/t(4;11): allogeneic stem cell transplantation (from sibling/MUD) or,
                alternatively, intensified high-dose therapy (2-4 &quot;hypercycles&quot;)with autologous
                stem cell support and anti CD20 MoAb (if CD20+), followed by maintenance. Each
                &quot;hypercycle&quot; consists of high-dose mercaptopurine-etoposide-melphalan (cycles no.
                1,3) or methotrexate-cytarabine (cycles no. 2,4)

             -  MRD unknown nonPh/t(4;11): treatment by clinical risk (SR: maintenance; HR, as per
                MRD+)

             -  Ph/t(4;11)+: allogeneic stem cell transplantation as soon as possible into complete
                remission; if a transplant is not possible, consolidation is as for HR patients.
                each cycle is supplemented by imatinib in Ph+ ALL

      The illustrated strategy aims to optimize postremission consolidation therapy by offering
      standard treatment &quot;only&quot; to patients at lowest risk of relapse (MRD-), thereby reducing the
      risks of high dose treatments (expected TRM from allogeneic SCT 20-30%), while maintaining
      the latter approach in MRD+ cases and very HR subsets.

      The prognostic role of MRD evaluation in unselected patients will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival at 5 years</measure>
    <time_frame>5 year from date of complete remission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission</measure>
    <time_frame>4 or 8 weeks from date of therapy start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years from date of diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relpase</measure>
    <time_frame>5 years from date of complete remission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remissional deaths</measure>
    <time_frame>4 weeks from date of therapy start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nonlethal toxicity</measure>
    <time_frame>5 years from date of therapy start</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Postremission consolidation based on MRD status</intervention_name>
    <description>Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MRD-guided therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Untreated Acute lymphoblastic leukemia or lymphoblastic lymphoma (T-cell, precursor
             B-cell)

          -  Age 15-65 years (older patients if biologically fit according to responsible
             physician)

          -  Written informed consent

        Exclusion Criteria:

          -  Any co-morbidity precluding the administration of intensive chemotherapy for adult ALL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bassan Renato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Ospedali Riuniti di Bergamo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia e TMO Ospedale San Maurizio</name>
      <address>
        <city>Bolzano</city>
        <state>BZ</state>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia e Centro TMO Ospedale Armando Businco</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Azienda Ospedaliera S.Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.S. Ematologia - Centro TMO Istituti Ospedalieri</name>
      <address>
        <city>Cremona</city>
        <state>CR</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Centro TMO Fondazione IRCSS Ospedale Maggiore</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e TMO Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - TMO Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MI</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncoematologia e TMO Dipartimento Oncologico</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia 2 Ospedale San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia Ospedale Umberto I</name>
      <address>
        <city>Mestre</city>
        <state>VE</state>
        <zip>30172</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia ed Ematologia Oncologica Institution Regione Veneto, ULSS n.13 - Presidi Ospedalieri di Noale, Mirano, Dolo</name>
      <address>
        <city>Noale</city>
        <state>VE</state>
        <zip>30033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Bassan R, Spinelli O, Oldani e et al. Minimal residual disease (MRD) and risk-oriented therapy in adult acute lymhoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstract) 106: abstract 1836, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009 Apr 30;113(18):4153-62. doi: 10.1182/blood-2008-11-185132. Epub 2009 Jan 13.</citation>
    <PMID>19141862</PMID>
  </results_reference>
  <results_reference>
    <citation>Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010 Aug 1;28(22):3644-52. doi: 10.1200/JCO.2010.28.1287. Epub 2010 Jul 6.</citation>
    <PMID>20606084</PMID>
  </results_reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2006</study_first_posted>
  <last_update_submitted>December 28, 2010</last_update_submitted>
  <last_update_submitted_qc>December 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Renato Bassan, MD</name_title>
    <organization>Ospedali Riuniti, Div. Ematologia, Bergamo, Italy</organization>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Adult patients</keyword>
  <keyword>Minimal residual disease</keyword>
  <keyword>Risk-oriented therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

